ATE245982T1 - Verwendung von 2-amino-6- trifluoromethoxybenzothiazol zur herstellung eines arzneimittels zur vorbeugung oder behandlung von zerebellumkrankheiten - Google Patents

Verwendung von 2-amino-6- trifluoromethoxybenzothiazol zur herstellung eines arzneimittels zur vorbeugung oder behandlung von zerebellumkrankheiten

Info

Publication number
ATE245982T1
ATE245982T1 AT99901703T AT99901703T ATE245982T1 AT E245982 T1 ATE245982 T1 AT E245982T1 AT 99901703 T AT99901703 T AT 99901703T AT 99901703 T AT99901703 T AT 99901703T AT E245982 T1 ATE245982 T1 AT E245982T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
trifluoromethoxybenzothiazole
cerebellum
diseases
Prior art date
Application number
AT99901703T
Other languages
English (en)
Inventor
Andrees Bohme
Alain Boireau
Thierry Canton
Assunta Imperato
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE245982T1 publication Critical patent/ATE245982T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT99901703T 1998-02-06 1999-02-03 Verwendung von 2-amino-6- trifluoromethoxybenzothiazol zur herstellung eines arzneimittels zur vorbeugung oder behandlung von zerebellumkrankheiten ATE245982T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9801402A FR2774592B1 (fr) 1998-02-06 1998-02-06 Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
PCT/FR1999/000230 WO1999039710A1 (fr) 1998-02-06 1999-02-03 Application du 2-amino-6- trifluoromethoxy- benzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet

Publications (1)

Publication Number Publication Date
ATE245982T1 true ATE245982T1 (de) 2003-08-15

Family

ID=9522673

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99901703T ATE245982T1 (de) 1998-02-06 1999-02-03 Verwendung von 2-amino-6- trifluoromethoxybenzothiazol zur herstellung eines arzneimittels zur vorbeugung oder behandlung von zerebellumkrankheiten

Country Status (18)

Country Link
US (1) US6245791B1 (de)
EP (1) EP1052989B1 (de)
JP (1) JP5127092B2 (de)
KR (1) KR100574378B1 (de)
AT (1) ATE245982T1 (de)
AU (1) AU761978B2 (de)
CA (1) CA2319686C (de)
DE (1) DE69909970T2 (de)
DK (1) DK1052989T3 (de)
EA (1) EA002676B1 (de)
ES (1) ES2199541T3 (de)
FR (1) FR2774592B1 (de)
IL (2) IL137608A0 (de)
NO (1) NO327819B1 (de)
NZ (1) NZ506124A (de)
PT (1) PT1052989E (de)
WO (1) WO1999039710A1 (de)
ZA (1) ZA99740B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
EP3265448B1 (de) * 2015-03-03 2021-12-29 Biohaven Pharmaceutical Holding Company Ltd. Riluzolprodrugs und deren verwendung
FI3706739T3 (fi) * 2017-11-12 2024-12-27 Biohaven Therapeutics Ltd Rilutsoliaihiolääkkeiden käyttö ataksioiden hoitamiseksi
CN112203692A (zh) * 2018-05-27 2021-01-08 拜尔哈文制药股份有限公司 利鲁唑口腔崩解片用于治疗疾病的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68901859T2 (de) * 1988-12-15 1993-01-14 Rhone Poulenc Sante 2-benzothiazolamin-derivate enthaltende arzneimittel, verbindungen und ihre herstellung.
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2714828B1 (fr) * 1994-01-12 1996-02-02 Rhone Poulenc Rorer Sa Application du riluzole dans le traitement des maladies mitochondriales.
FR2726271B1 (fr) * 1994-10-26 1996-12-06 Rhone Poulenc Rorer Sa Derives de 6-polyfluoroalcoxy-2-aminobenzothiazole

Also Published As

Publication number Publication date
CA2319686C (fr) 2009-06-23
ES2199541T3 (es) 2004-02-16
FR2774592B1 (fr) 2000-03-17
US6245791B1 (en) 2001-06-12
AU761978B2 (en) 2003-06-12
KR20010040671A (ko) 2001-05-15
AU2171199A (en) 1999-08-23
EA002676B1 (ru) 2002-08-29
EP1052989B1 (de) 2003-07-30
NZ506124A (en) 2003-07-25
JP2002502819A (ja) 2002-01-29
IL137608A (en) 2006-09-05
NO20003785L (no) 2000-07-24
ZA99740B (en) 1999-08-02
DE69909970T2 (de) 2004-05-27
EA200000816A1 (ru) 2001-02-26
EP1052989A1 (de) 2000-11-22
DK1052989T3 (da) 2003-11-17
IL137608A0 (en) 2001-07-24
CA2319686A1 (fr) 1999-08-12
NO20003785D0 (no) 2000-07-24
DE69909970D1 (de) 2003-09-04
PT1052989E (pt) 2003-12-31
WO1999039710A1 (fr) 1999-08-12
JP5127092B2 (ja) 2013-01-23
FR2774592A1 (fr) 1999-08-13
NO327819B1 (no) 2009-09-28
KR100574378B1 (ko) 2006-04-26

Similar Documents

Publication Publication Date Title
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
ES2282685T3 (es) Derivados de hidroxietilamina para el tratamiento de la enfermedad de alzheimer.
GB0223038D0 (en) Therapeutic compounds
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
MXPA04003245A (es) Hidroxipropilaminas.
MXPA05002420A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos.
TW200505828A (en) Substituted ureas and carbamates useful in the treatment of alzheimer's disease
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
ES2189357T3 (es) Compustos isocromano y procedimiento para su produccion.
WO2006026204A3 (en) Novel gamma-lactams as beta-secretase inhibitors
ATE245982T1 (de) Verwendung von 2-amino-6- trifluoromethoxybenzothiazol zur herstellung eines arzneimittels zur vorbeugung oder behandlung von zerebellumkrankheiten
ATE247956T1 (de) Verwendung von modafinil zur herstellung eines arzneimittels zur behandlung von vigilanzstörungen im zusammenhang mit myopathien
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
ATE492285T1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE257702T1 (de) Verwendung von 2-imidazolyl-substituierten carbinolen zur herstellung eines medikaments zur behandlung oder prophylaxe von durch ischämischen zuständen bewirkten krankheiten
DE60219680D1 (de) Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit
ATE263565T1 (de) Verwendung von 8,9-dehydroestron zur herstellung eines arzneimittels zur behandlung von durch freie radikale verursachte krankheiten
ATE192650T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE324111T1 (de) Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen
DE69610045D1 (de) Verwendung eines Rohpflanzenextraktes zur Herstellung eines Arzneimittels zur Behandlung von HIV-Infektionen
ATE248607T1 (de) Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
ATE186640T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen
ATE350034T1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus
DE60216090D1 (de) Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1052989

Country of ref document: EP